Gonapeptyl Depot (Triptorelin)

Gonapeptyl Depot is indicated for medical conditions that benefit from long‑term suppression of luteinizing hormone (LH) and follicle‑stimulating hormone (FSH), thereby decreasing sex steroid production.

• Advanced prostate cancer as part of androgen deprivation therapy.
• Management of moderate to severe endometriosis to reduce lesion growth.
• Treatment of symptomatic uterine fibroids to control bleeding.
• Control of central precocious puberty in children.
• Adjunct in assisted reproductive technology to prevent premature ovulation.
• Use in hormone‑dependent breast cancer as part of experimental protocols.

The pharmacological action of Gonapeptyl Depot can produce a range of adverse effects, which are generally categorized as common or serious. These effects may vary with treatment duration, dosage, and individual health status.

Common

• Transient hot flashes or sweating episodes.
• Mild injection‑site pain, redness, or swelling.
• Headache or mild dizziness.
• Decreased libido or erectile dysfunction.
• Irregular menstrual bleeding or amenorrhea.
• Nausea or mild gastrointestinal discomfort.

Serious

• Cardiovascular complications such as hypertension or thromboembolic events.
• Severe allergic reactions including rash, angioedema, or anaphylaxis.
• Significant loss of bone mineral density leading to osteoporosis.

Before initiating Gonapeptyl Depot, clinicians should evaluate several precautionary factors to minimize risks and ensure appropriate patient selection.

• Contraindicated in pregnancy; effective contraception is required for women of childbearing potential.
• Assess fertility intentions, as treatment can cause temporary or prolonged infertility.
• Evaluate cardiovascular health, especially in patients with hypertension or thrombotic history.
• Monitor bone mineral density during long‑term therapy.
• Review liver and kidney function, adjusting therapy if impairment is present.
• Verify absence of hypersensitivity to triptorelin or formulation excipients.
• Regularly monitor serum LH, FSH, and sex hormone levels to gauge therapeutic effect.

Gonapeptyl Depot may interact with other medicines, affecting its efficacy or safety profile.

Avoid

• Concurrent use with other GnRH agonists or antagonists, which may cause excessive hormone suppression.
• Combination with hormonal contraceptives that could mask the intended therapeutic effect.

Use with caution

• Drugs metabolized by CYP450 enzymes, as triptorelin may alter their plasma concentrations.
• Medications that prolong the QT interval, increasing cardiac risk.
• Agents influencing bone metabolism, such as bisphosphonates or glucocorticoids.
• Anticoagulants, due to potential additive effects on bleeding risk.